Polaroid Therapeutics Strengthens Leadership Team with Appointment of Professor Sebastian Probst as Clinical Specialist Advisor

Polaroid Therapeutics welcomes Professor Sebastian Probst, a global authority in wound care, as its Clinical Specialist Advisor. Probst’s extensive clinical experience and research will bolster Polaroid Therapeutics’ mission to develop innovative wound care solutions. Professor…

  • Polaroid Therapeutics welcomes Professor Sebastian Probst, a global authority in wound care, as its Clinical Specialist Advisor.
  • Probst’s extensive clinical experience and research will bolster Polaroid Therapeutics’ mission to develop innovative wound care solutions.
  • Professor Probst will leverage his expertise to guide product development and improve patient outcomes.

ZURICH, SWITZERLAND, 03 SEPTEMBER 2024: Polaroid Therapeutics, the Swiss-based biotech start-up focused on tackling antimicrobial resistance, today announces the appointment of Sebastian Probst as its Clinical Specialist Advisor. Probst is a notable figure within the industry and brings unparalleled expertise in wound care, patient-centered care, and the integration of advanced technologies to the company.

With a distinguished career spanning decades, Professor Probst has established himself as an authority in the field of wound care. His extensive clinical experience, coupled with his groundbreaking research, has significantly advanced the understanding and treatment of chronic and palliative wounds. As the former President of the European Wound Management Association (EWMA), Professor Probst has played a pivotal role in shaping the future of wound care on a global scale.


“Professor Probst’s appointment reflects our unwavering commitment to building a world-class team of experts dedicated to improving patient outcomes in wound care,” said Ran Frenkel, CEO of Polaroid Therapeutics. “His exceptional knowledge and passion for patient-centered care perfectly align with our mission. Professor Probst’s insights will be invaluable as we continue to develop innovative solutions that address the critical challenges faced by patients and healthcare providers.”

Professor Probst will utilise his deep understanding of patient needs and knowledge sector innovation to help guide the company’s strategic approach in the coming months.  His expertise in bridging the gap between clinical practice and product development will be invaluable as the company strives to improve patient outcomes and address unmet needs in wound care, which the WHO has identified as one of the top global public health threats. In 2019 alone, mismanaged wound care was directly responsible for 1.27 million deaths globally, and contributed to a further 4.95 million[1].


Professor Probst adds: “I am honoured to join Polaroid Therapeutics Clinical Specialist Advisor. The company’s dedication to advancing wound care through cutting-edge solutions is truly inspiring and echoes so much of my work to date. I look forward to contributing my expertise and working collaboratively with the team to improve the lives of patients with wounds.”


[1] WHO

ENDS

Notes to Editor

About Polaroid Therapeutics:

Polaroid Therapeutics is a Swiss-based biotech start-up in the development of innovative antimicrobial technology. Incubated and spun off by Polaroid, the brand that pioneered the chemistry behind analogue instant photography. Polaroid  Therapeutics mission is to bring to life the best of Polaroid’s vision of creating a more human and meaningful world through cutting-edge technology and research.

Founded in 2022, Polaroid Therapeutics is developing antimicrobial therapies based on proprietary QPEI technology designed to prevent and inhibit infections in multiple indications, such as acute and chronic wounds. This unique technology is a breakthrough solution without antimicrobial resistance, regarded as the most prominent global threat to health.

Contact: 

Liam Rawson

polaroidTX@ragency.com